ReviewIndian journal of ophthalmology2019
Intraocular medulloepithelioma - A review of clinical features, DICER 1 mutation, and management.
Review in Indian journal of ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Surveillance recommendations for DICER1 pathogenic variant carriers: a report from the SIOPE Host Genome Working Group and CanGene-CanVar Clinical Guideline Working Group.Familial cancer · 2021Guideline
- Malignant teratoid medulloepithelioma with retinal invasion masquerading as vasoproliferative retinal tumor in an adult.American journal of ophthalmology case reports · 2026Article
- A rare case of adenoma of the nonpigmented ciliary epithelium managed with a triple procedure: a case report.Frontiers in medicine · 2026Article
- Ultrasound Biomicroscopy in the Diagnosis and Management of Iris and Ciliary Body Tumors: A Comprehensive Review.Ocular oncology and pathology · 2025Review
- Intraocular Tumors in Horses: Diagnosis, Tumor Classification, Oncologic Assessment and Therapy.Veterinary sciences · 2025Review
- Malignant Teratoid Medulloepithelioma with Rhabdomyosarcomatous Differentiation.Ocular oncology and pathology · 2025Article
- The development and the genetic diseases of the ciliary body.Cell insight · 2024Review
- Review
- [DICER1 syndrome: clinical variety endocrine manifestations and features of diagnostics].Problemy endokrinologii · 2023Review
- Analysis of clinical and pathological features of ciliary body medulloepithelioma.International journal of ophthalmology · 2023Article
- Posterior choroidal leiomyoma: new findings from a case and literature review.International journal of ophthalmology · 2023Review
- Ciliary body medulloepithelioma treated with intra-operative brachytherapy after fine needle aspiration biopsy.Journal of contemporary brachytherapy · 2022Article
- Co-activation of Sonic hedgehog and Wnt signaling in murine retinal precursor cells drives ocular lesions with features of intraocular medulloepithelioma.Oncogenesis · 2021Article
- Rare presentation of ciliary body medulloepithelioma with lens particle-induced uveitis.BMJ case reports · 2021Article
- Subconjunctival Mass as Rare Presentation of Even Rarer Intraocular Medulloepithelioma: A Case Report.JNMA; journal of the Nepal Medical Association · 2021Article
- Successful treatment of ciliary body medulloepithelioma with intraocular melphalan chemotherapy: a case report.BMC ophthalmology · 2020Article
- Histopathology of Intraocular Medulloepithelioma following Iodine-125 Plaque Brachytherapy.Case reports in ophthalmologyArticle
- Plaque Brachytherapy for DICER1-Associated Ciliary Body Medulloepithelioma.Journal of current ophthalmologyArticle
- Optic disc and peripapillary tumors.Taiwan journal of ophthalmologyReview
- Ciliary Body Leiomyoma.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intraocular medulloepithelioma is a nonhereditary neoplasm of childhood arising from primitive medullary epithelium. It most often involves the ciliary body. Most patients present between 2 and 10 years of age with loss of vision, pain, leucocoria, or conjunctival congestion. The mass appears as a grey-white ciliary body lesion with intratumoral cysts. Presence of a neoplastic cyclitic membrane with extension to retrolental region is characteristic. Secondary manifestations like cataract and neovascular glaucoma may be present in up to 50% and 60% patients, respectively. These could be the first signs for which, unfortunately, about 50% patients undergo surgery before recognition of the hidden tumor. Systemic correlation with pleuropulmonary blastoma (DICER1 gene) has been documented in 5% cases. Histopathology shows primitive neuroepithelial cells arranged as cords closely resembling the primitive retina. Histopathologically, the tumor is classified as teratoid (containing heteroplastic elements) and nonteratoid (containing medullary epithelial elements), each of which are further subclassified as benign or malignant. Retinoblastoma-like and sarcoma-like areas may be seen within the tissue. The treatment modality depends on tumor size and extent of invasion. For small localized tumors (≤3-4 clock hours), conservative treatments with cryotherapy, plaque radiotherapy, or partial lamellar sclerouvectomy (PLSU) have been used. Plaque brachytherapy is generally preferred for best tumor control. Advanced and extensive tumors require enucleation. Rare use of intra-arterial and intravitreal chemotherapy has been employed. Systemic prognosis is favorable, but those with extraocular extension and orbital involvement show risk for local recurrence and metastatic disease, which can lead to death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.